Antares Pharma (ATRS) Shares are Up 1.2%

Antares Pharma (ATRS) : Traders are bullish on Antares Pharma (ATRS) as it has outperformed the S&P 500 by a wide margin of 34.05% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.04%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.2% in the last 1 week, and is up 33.33% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 13.09% and the 50-Day Moving Average is 32.51%.The 200 Day SMA reached 57.74%


Antares Pharma (NASDAQ:ATRS): The stock opened in the green at $1.77 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $1.78 and a low of $1.66 for the day. The stock did not find buyers even at the lows and closed at $1.68 recording a loss of -5.08%. 1,524,162 shares exchanged hands during the trading day. The stock had closed at $1.68 in the previous days trading.

Antares Pharma (ATRS) stock is expected to deviate a maximum of $0.58 from the average target price of $2.67 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $3 and the most muted being $2.

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *